These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 19428401)
1. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401 [TBL] [Abstract][Full Text] [Related]
2. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. Linazasoro G; J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related]
4. A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory. Gibbs SE; D'Esposito M Neuroscience; 2006 Apr; 139(1):359-71. PubMed ID: 16458442 [TBL] [Abstract][Full Text] [Related]
5. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. Relja M; Klepac N J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675 [TBL] [Abstract][Full Text] [Related]
7. Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease. Costa A; Carlesimo GA; Caltagirone C; Mazzone P; Pierantozzi M; Stefani A; Peppe A Parkinsonism Relat Disord; 2010 Jan; 16(1):64-7. PubMed ID: 19502095 [TBL] [Abstract][Full Text] [Related]
8. Pergolide effect on cognitive functions in early-mild Parkinson's disease. Brusa L; Tiraboschi P; Koch G; Peppe A; Pierantozzi M; Ruggieri S; Stanzione P J Neural Transm (Vienna); 2005 Feb; 112(2):231-7. PubMed ID: 15365788 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685 [TBL] [Abstract][Full Text] [Related]
10. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Moustafa AA; Sherman SJ; Frank MJ Neuropsychologia; 2008 Nov; 46(13):3144-56. PubMed ID: 18687347 [TBL] [Abstract][Full Text] [Related]
11. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease. Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374 [TBL] [Abstract][Full Text] [Related]
12. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease. Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999 [TBL] [Abstract][Full Text] [Related]
13. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022 [TBL] [Abstract][Full Text] [Related]
14. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349 [TBL] [Abstract][Full Text] [Related]
15. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. Lemke MR; Brecht HM; Koester J; Reichmann H J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808 [TBL] [Abstract][Full Text] [Related]
16. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082 [TBL] [Abstract][Full Text] [Related]
17. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709 [TBL] [Abstract][Full Text] [Related]
18. Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers. Mehta MA; Hinton EC; Montgomery AJ; Bantick RA; Grasby PM J Psychopharmacol; 2005 Jan; 19(1):29-38. PubMed ID: 15671126 [TBL] [Abstract][Full Text] [Related]
19. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473 [TBL] [Abstract][Full Text] [Related]
20. Impaired reproduction of second but not millisecond time intervals in Parkinson's disease. Koch G; Costa A; Brusa L; Peppe A; Gatto I; Torriero S; Gerfo EL; Salerno S; Oliveri M; Carlesimo GA; Caltagirone C Neuropsychologia; 2008 Apr; 46(5):1305-13. PubMed ID: 18215403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]